Systems pharmacology-based study of Tanreqing injection in airway mucus hypersecretion

Liu, Wei; Zhang, Xiawei; Mao, Bing; Jiang, Hongli

doi:10.1016/j.jep.2019.112425

Cited by 29 publications

(21 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[ 8 , 9 ] In the diagnosis and treatment of new type of coronavirus pneumonia in China, it has been recommended to use Tanreqing Injection for adjuvant treatment for patients with systemic inflammatory response syndrome or / multiple organ failure. [ 10 ] Three systematic reviews of Tanreqing Injection in the treatment of viral pneumonia were published in 2012, 2014 and 2015, all confirming the effectiveness of Tanreqing Injection in the treatment of viral pneumonia, [ 11 , 12 ] but whether Reducing mortality in patients with viral pneumonia is controversial.…”

Section: Introductionmentioning

confidence: 99%

Effects and safety of Tanreqing injection on viral pneumonia: Retraction

Qiu

Pan

et al. 2020

Medicine

View full text Add to dashboard Cite

Background: Influenza-related viral pneumonia is a severe threat to human health, which has caused high morbidity and mortality each year. The objective of this study was to assess the efficacy and safety of Tanreqing Injection therapy in patients with viral pneumonia. Materials and methods: This protocol established in this study has been reported following the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols. Web of Science, PubMed, EMBASE and the Cochrane Library were searched for clinical randomized trials in cases with viral pneumonia until 1st of July 2020. We will use a combination of Medical Subject Heading and free-text terms with various synonyms to search based on the Eligibility criteria. Two investigators independently reviewed the included studies and extracted relevant data. The relative risk (RR) and 95% confidence intervals (CIs) of were used as effect estimate. I-square (I 2 ) test, substantial heterogeneity, sensitivity analysis and publication bias assessment will be performed accordingly. Stata 14.0 and Review Manger 5.3 are used for meta-analysis and systematic review. Results: The results will be published in a peer-reviewed journal. Conclusion: The results of this review will be widely disseminated through peer-reviewed publications and conference presentations. This evidence may also provide helpful evidence of whether Tanreqing Injection therapy was efficient and safe in patients with viral pneumonia. PROSPERO registration number: CRD42020164164.

show abstract

Section: Introductionmentioning

confidence: 99%

Effects and safety of Tanreqing injection on viral pneumonia: Retraction

Qiu

Pan

et al. 2020

Medicine

View full text Add to dashboard Cite

show abstract

“…It is speculated that the mechanism may be some molecules in Tanreqing, combining with HEp-2 cells or the corresponding parts of RSV surface, and changing its conformation or the number and structure of viral receptors on cell membrane to inhibit RSV penetration; during treatment and direct inactivation, the mechanism of Tanreqing inhibiting RSV proliferation and inactivation in vitro may be: Tanreqing could inhibit the replication of viral nucleic acid or prevent viral protein synthesis; some components of Tanreqing can combine with specific parts of RSV surface to make RSV inactive; Tanreqing injection stimulates the cell to secrete some molecular active substances, such as interleukin and interferon, to inhibit the proliferation of virus or kill directly, but its detailed mechanism needs further study. [ 24 , 25 ] Ganciclovir is a widely used antiviral drug with high efficiency and broad-spectrum. The mechanism of ganciclovir inhibiting virus is as follows: on the 1 hand, it can directly penetrate into viral DNA and terminate the extension process of DNA replication; on the other hand, it competes to inhibit viral DNA polymerase and prevent DNA replication.…”

Section: Discussionmentioning

confidence: 99%

The effectiveness and safety of Tanreqing Injection combined with ganciclovir on the treatment of respiratory syncytial virus pneumonia in children

2020

View full text Add to dashboard Cite

Background: Based on the Theory of Traditional Chinese Medicine, this study systematically evaluated the effectiveness and safety of Chinese medicine preparation Tanreqing injection combined with ganciclovir on the treatment of respiratory syncytial virus pneumonia in children, and provided new ideas and methods for the treatment of respiratory syncytial virus pneumonia (RSVP) in children. At the same time, it also studies the effectiveness and safety of the combination of Chinese and Western medicine on the treatment of related diseases from the direction of evidence-based medicine. Methods: The relevant literature was searched by the computer in the electronic network databases, the retrieved databases include Chinese database and English database, English database includes PubMed, Cochrane Library, Embase and Web of Science. Chinese database includes: CNKI, SinoMed, WangFang Date, VIP and other networks electronic full-text database, conducting a randomized controlled trial of Tanreqing Injection combined with ganciclovir (study group) and ganciclovir alone (control group) on the treatment of RSVP in children and the retrieval time limit is set from the establishment of each database to July 1, 2020. According to the inclusion and exclusion criteria, the literature is independently searched and screened by 2 researchers, and conducting the full-text retrieval and evaluation of the research to be included, and extracting the information and checking it after reading the full-text; In case of disagreement, a third researcher will be invited to participate, and the decision is made after discussion by the 3 researchers. They were using the bias risk assessment tool provided by the Cochrane Handbook for Systematic Reviews of Interventions 3.0.2 to evaluate the selected literature. They were using RevMan 5.3 statistical software to conduct statistical analysis. Results: This study will be carried out in full accordance with the steps of systematic review as required in the Cochrane Handbook for Systematic Reviews of Interventions. All research results will be published publicly in international academic journals with peer review. Conclusion: After the meta-analysis of Tanreqing injection combined with ganciclovir on the treatment of RSVP in children, this paper will give a scientific and objective judgment on the effectiveness and safety of the combined use of Chinese and Western medicine on the treatment of RSVP in children, to provide evidence-based medical evidence for the clinical application, effectiveness and safety of Chinese and Western medicine combined on the treatment of RSVP in children. PROSPERO registration number: OSF platform, registration number: j2bz5.

show abstract

“…Wei Liu et al discovered that TRQI might treat airway mucus hypersecretion by regulating the interleukin-17 (IL-17) signaling pathway and its downstream protein MUC5AC. An in vivo experiment showed that TRQI could significantly inhibit excessive secretion of LPS-stimulated MUC5AC and expression of TNF-a, interleukin-6 (IL-6), IL-8, and IL-17A in terms of protein and mRNA levels (Liu W. et al, 2019). Animal experiments conducted by Wei Liu et al showed that TRQI inhibited airway inflammation caused by LPS through the MAPK/NF-kB pathway, and showed a dose-dependent effect (Liu et al, 2016).…”

Section: Progress Of Pharmacological Research On Trqimentioning

confidence: 99%

Chinese Patent Medicines in the Treatment of Coronavirus Disease 2019 (COVID-19) in China

et al. 2020

View full text Add to dashboard Cite

Background: Coronavirus Disease 2019 (COVID-19) is an emerging and rapidly evolving disease, with no recommended effective anti-coronavirus drug treatment. Traditional Chinese Patent Medicines (CPMs) have, however, been widely used to treat COVID-19 in China, and a number of clinical practice results have shown them to have a significant role in its treatment. Consequently, numerous guidelines and expert consensus have recommended the use of CPMs to treat COVID-19. Aim of the Study: The objectives of this review are to provide up-to-date information on the pharmacology and clinical research on CPMs in the treatment of COVID-19, discuss the research findings, and to better guide clinical application and scientific research on CPMs in the treatment of COVID-19. Methods: The frequencies of CPM recommendations by guidelines and expert consensus for treatment of COVID-19 in China were ranked. This report identifies the top 10 CPMs, which include Huoxiang Zhengqi capsule (HXZQC), Lianhua Qingwen capsule (LHQWC), Jinhua Qinggan granule (JHQGG), Shufeng Jiedu capsule (SFJDC), Tanreqing injection (TRQI), Xiyanping injection (XYPI), Xuebijing injection (XBJI), Shenfu injection (SFI), Shengmai injection (SMI), and Angong Niuhuang pill (AGNHP). Relevant studies from 2000 to 2020 on these top 10 CPMs, covering usage, dosage, mechanism, curative effect, and precautions, were collected from pharmacopoeia, reports, and theses via library and digital databases (including PubMed, CNKI, Google Scholar, Web of Science, and Elsevier). Results: The properties of the top 10 CPMs included antiviral, antibacterial, antiinflammatory, antipyretic and analgesic, anti-acute lung injury, anti-shock, immune regulation, and enhancement of pulmonary function. In addition, clinical research results and Chinese treatment data showed that the CPMs had good therapeutic efficacy in the treatment of COVID-19, and adverse reactions were minimal.

show abstract

Systems pharmacology-based study of Tanreqing injection in airway mucus hypersecretion

Cited by 29 publications

References 38 publications

Effects and safety of Tanreqing injection on viral pneumonia: Retraction

Effects and safety of Tanreqing injection on viral pneumonia: Retraction

The effectiveness and safety of Tanreqing Injection combined with ganciclovir on the treatment of respiratory syncytial virus pneumonia in children

Chinese Patent Medicines in the Treatment of Coronavirus Disease 2019 (COVID-19) in China

Contact Info

Product

Resources

About